Graves Disease

Clinical Trial Title A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Patients With Graves’ Disease
Trial Status Open to Enrollment
Start Date 01/24/2025
Location endocrinology-tualatin
Trial Type Diabetes/Endocrinology
Specific Condition Graves Disease
Description

This is a study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment.

The primary objective of this study is to evaluate the efficacy of IMVT-1402 versus placebo as assessed by T3 (total triiodothyronine [T3] or free triiodothyronine [FT3]), free thyroxine (FT4), thyroid-stimulating hormone (TSH), and ATD dose at Week 26
Eligibility Criteria
  • Male or female participants aged ≥ 18 years to 75 years
  • Participants with diagnosis of GD who are hyperthyroid despite ATD treatment
IRB Number 10902
Notes https://clinicaltrials.gov/study/NCT06727604?cond=Graves%20Disease&intr=IMVT-1402&viewType=Card&rank=2
Principal Investigator Troy Dillard, MD
Contact Name Madeline Cooke
Contact Phone 503-413-7094
Contact Fax 503-413-6861
Contact E-Mail macooke@lhs.org